Aliases & Classifications for Opioid Dependence 1

MalaCards integrated aliases for Opioid Dependence 1:

Name: Opioid Dependence 1 54 29
Opioid Dependence, Susceptibility to, 1 13

External Ids:

OMIM 54 610064

Summaries for Opioid Dependence 1

MalaCards based summary : Opioid Dependence 1, also known as opioid dependence, susceptibility to, 1, is related to fascioscapulohumeral muscular dystrophy 2, digenic. An important gene associated with Opioid Dependence 1 is ODS1 (Opioid Dependence, Susceptibility To, 1). The drugs Buprenorphine and Heroin have been mentioned in the context of this disorder. Affiliated tissues include testes and brain.

Description from OMIM: 610064

Related Diseases for Opioid Dependence 1

Diseases related to Opioid Dependence 1 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 fascioscapulohumeral muscular dystrophy 2, digenic 9.5 ODS1 OPRM1

Symptoms & Phenotypes for Opioid Dependence 1

Clinical features from OMIM:

610064

Drugs & Therapeutics for Opioid Dependence 1

Drugs for Opioid Dependence 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
2
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 561-27-3 5462328
3
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 465-65-6 5284596
4
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 16590-41-3 5360515
5
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
6
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
7
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
8
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
9
Isoniazid Approved Phase 4 54-85-3 3767
10
Rifapentine Approved Phase 4 61379-65-5 6323497
11
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
12
Menthol Approved Phase 4 2216-51-5 16666
13 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1
22 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1
24 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
31 Anti-Infective Agents Phase 4,Phase 3,Phase 1
32 Anesthetics, Local Phase 4,Phase 2,Phase 3,Phase 1
33 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Anesthetics, Dissociative Phase 4
35 Anesthetics, General Phase 4,Phase 1
36 Anesthetics, Intravenous Phase 4,Phase 1
37 Desvenlafaxine Succinate Phase 4 386750-22-7
38 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 1,Phase 2
39 Antiviral Agents Phase 4,Phase 3,Phase 1
40 interferons Phase 4,Phase 3
41 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
42 Anti-Bacterial Agents Phase 4,Phase 1
43 Antibiotics, Antitubercular Phase 4,Phase 1
44 Antimetabolites Phase 4,Phase 3,Phase 1
45 Antitubercular Agents Phase 4,Phase 1
46 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antipsychotic Agents Phase 4
48 Hypolipidemic Agents Phase 4
49 Lipid Regulating Agents Phase 4
50 Quetiapine Fumarate Phase 4 111974-72-2

Interventional clinical trials:

(show top 50) (show all 245)

id Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
4 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
5 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
6 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
7 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
8 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
9 Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice Completed NCT00007527 Phase 4 naloxone;buprenorphine
10 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
11 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
12 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
13 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
14 Desvenlafaxine in Opioid-Dependent Patients Completed NCT02200406 Phase 4 Desvenlafaxine
15 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
16 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
17 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
18 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
19 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
20 Extended Release Naltrexone for Opioid-Dependent Youth Recruiting NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
21 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
22 Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings Enrolling by invitation NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
23 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Not yet recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
24 Liposomal Bupivacaine in Ambulatory Hand Surgery Not yet recruiting NCT02933814 Phase 4 Liposomal Bupivicaine
25 Anxiety in Recovering Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
26 Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents Withdrawn NCT01015066 Phase 4 Buprenorphine/naloxone;Naltrexone
27 Comparing Opium Tincture (OT) With Methadone for Substitution Treatment of Opioid Dependence Unknown status NCT02502175 Phase 3 opium;methadone
28 Combined Therapy of Methadone and Dextromethrophan Unknown status NCT01189097 Phase 3 Dextromethorphan;Dextromethorphan
29 Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1 Completed NCT00015171 Phase 3 Buprenorphine/naloxone
30 A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction Completed NCT01114308 Phase 3 Probuphine (buprenorphine implant);placebo implant;Buprenorphine
31 Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal Completed NCT01863186 Phase 3 Lofexidine HCl;Placebo;Open Label Lofexidine HCL
32 Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults Completed NCT01052662 Phase 2, Phase 3 Memantine;Memantine;Placebo
33 ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals Completed NCT00834080 Phase 3 Medisorb naltrexone 380 mg
34 Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence Completed NCT02651584 Phase 3 CAM2038 subcutaneous injection;SL BPN tablets;placebo subcutaneous (SC) injections;SL placebo tablets
35 HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group. Completed NCT00147784 Phase 3 Ribavirin;Pegylated Interferon
36 Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence Completed NCT01848054 Phase 3 Buprenorphine/naloxone sublingual tablets;Buprenorphine
37 Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1 Completed NCT00078130 Phase 3 Buprenorphine/naloxone
38 Lofexidine for Opiate Withdrawal - 1 Completed NCT00032942 Phase 3 Lofexidine
39 Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) Completed NCT01447212 Phase 3 Hydromorphone, Injectable;Diacetylmorphine, injectable;Hydromorphone, liquid oral;Diacetylmorphine, liquid oral
40 Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1 Completed NCT00078117 Phase 3 Buprenorphine
41 NAOMI: A Study to Compare Medically-prescribed Heroin With Oral Methadone in Chronic Opiate Addiction Completed NCT00175357 Phase 3 Methadone;Diamorphine hydrochloride
42 RCT Comparing Methadone and Buprenorphine in Pregnant Women Completed NCT00271219 Phase 3 Methadone;Buprenorphine
43 Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Completed NCT00032968 Phase 3 Buprenorphine/naloxone
44 ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®) Completed NCT01218997 Phase 3 Medisorb naltrexone 380 mg;Oral naltrexone 50 mg
45 Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site Completed NCT00781898 Phase 2, Phase 3 Depot naltrexone
46 Methadone Maintenance & HIV Risk in Ukraine Completed NCT00351026 Phase 3 Methadone
47 Linking Hospitalized Injection Drug Users to Buprenorphine Completed NCT00987961 Phase 3
48 Prescription Opioid Addiction Treatment Study (POATS) Completed NCT00316277 Phase 3
49 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1 Completed NCT00032955 Phase 3 Buprenorphine/naloxone
50 The German Project of Heroin Assisted Treatment of Opiate Dependent Patients Completed NCT00268814 Phase 3 Diacetylmorphine;Methadone

Search NIH Clinical Center for Opioid Dependence 1

Genetic Tests for Opioid Dependence 1

Genetic tests related to Opioid Dependence 1:

id Genetic test Affiliating Genes
1 Opioid Dependence 1 29

Anatomical Context for Opioid Dependence 1

MalaCards organs/tissues related to Opioid Dependence 1:

39
Testes, Brain

Publications for Opioid Dependence 1

Variations for Opioid Dependence 1

ClinVar genetic disease variations for Opioid Dependence 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 OPRM1 NM_001008503.2(OPRM1): c.118A> G (p.Asn40Asp) single nucleotide variant drug response rs1799971 GRCh37 Chromosome 6, 154360797: 154360797

Expression for Opioid Dependence 1

Search GEO for disease gene expression data for Opioid Dependence 1.

Pathways for Opioid Dependence 1

GO Terms for Opioid Dependence 1

Sources for Opioid Dependence 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....